Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 11/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4046793 | 0.82 | NR4A2 (0.47) | NR4A2CREBBPMAP2K1 | |
| SCHEMBL1156403 | 0.80 | NR4A2 (0.49) | NR4A2CREBBPMAPTMAP2K1TSHR | |
| SCHEMBL6082830 | 0.80 | TSHR (0.52) | MAPTTSHRLMNAKDM4EGAA | |
| SCHEMBL6022280 | 0.79 | NR4A2 (0.45) | NR4A2CREBBPMAP2K1LMNA | |
| SCHEMBL22289949 | 0.79 | GRM1 (0.37) | — | |
| SCHEMBL29951791 | 0.77 | NR4A2 (0.47) | NR4A2CREBBPMAPTMAP2K1HTT | |
| SCHEMBL754468 | 0.76 | MAPT (0.47) | NR4A2CREBBPMAPTMAP2K1HTT | |
| SCHEMBL27224002 | 0.76 | NR4A2 (0.43) | NR4A2CREBBPMAPTMAP2K1HTT | |
| SCHEMBL353039 | 0.76 | BRPF1 (0.44) | KDM4EGAA | |
| SCHEMBL547358 | 0.76 | NOTUM (0.50) | KDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | FOGHORN THERAPEUTICS INC. (US) | 2025-12-30 | — | — | US | disclosed |
| CN-115335373-B | Compounds and uses thereof | 福宏治疗公司 | 2025-05-20 | — | — | CN | disclosed |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4097096-A2 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| CN-115335373-A | Compound and use thereof | 福宏治疗公司 | 2022-11-11 | — | — | CN | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2022-04-21 | — | — | US | disclosed |
| WO-2021155321-A2 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2020160100-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| US-10662173-B2 | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2020-05-26 | — | — | US | disclosed |
| US-20170342051-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-11-30 | — | — | US | disclosed |
| US-9765056-B2 | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-09-19 | — | — | US | disclosed |
| US-20160152599-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2016-06-02 | — | — | US | disclosed |
| US-5331006-A | Cholecystokinin, antisecretory agents | WARNER-LAMBERT COMPANY (US) | 1994-07-19 | — | — | US | disclosed |
| WO-1992004025-A1 | AMINO ACID ANALOGS AS CCK ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1992-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342051-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | RB1, IDO1, BCL2A1 | NR4A2 2378/4885CREBBP 2478/4885MAPT 1338/4885 |
| US-10662173-B2 | Indole and pyrrole compounds, a process for their preparation and pharmaceutical compositions containing them | RB1, IDO1, BCL2A1 | NR4A2 2378/4885CREBBP 2478/4885MAPT 1338/4885 |
| US-20230348452-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, BRCA1 | NR4A2 2234/4885CREBBP 618/4885MAPT 1920/4885 |
| US-12509453-B2 | BRM/BRG1 inhibitors and uses thereof | SMARCC1, SMARCC2, SMARCA1 | NR4A2 534/4885CREBBP 169/4885MAPT 4354/4885 |
| US-20160152599-A1 | INDOLE AND PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | IDO1, IDO2, NFATC1 | NR4A2 1838/4885CREBBP 3167/4885MAPT 1975/4885 |
| US-20220119378-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | NR4A2 2024/4885CREBBP 607/4885MAPT 2074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.